AUSTIN, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - For most of the history of antibody discovery, the hard part was producing candidates. Generative models, high-throughput assays
Danaher companies IDT and Aldevron bring gene editing expertise and mRNA manufacturing together to help researchers tackle efficiency, targeting, and workflow challenges in base and prime editing
PE Ultra mRNA,
WASHINGTON, Nov. 2, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that President and Chief Executive Officer, Julie Sawyer Montgomery, will be presenting at the UBS Global Healthcare Conference in Palm
WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) today announced results for the third quarter 2026. All results in this release reflect only continuing operations and period-to-period
Collaboration will bring together NVIDIA AI technologies and Danaher's scientific instruments, laboratory workflows and dataWASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) today announced a
WASHINGTON, Oct. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or "the Company") today announced the appointment of Daniel L. Comas and Robert Hershberg, M.D., Ph.D., to the Danaher
Helping researchers to move from discovery to breakthrough up to 8x faster by combining AI, automation and innovation from across Danaher's ecosystem of industry-leading technologiesWASHINGTON, Oct. 7, 2026
WASHINGTON, Oct. 1, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or "the Company") announced that, effective today, Julie Sawyer Montgomery has assumed the roles of President and Chief
WASHINGTON, Sept. 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00
Co-developed offering connects Integrated DNA Technologies’ CRISPR engineering and analysis expertise with Aldevron’s mRNA manufacturing capabilities, helping customers move from discovery toward clinical development
WASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on
Rainer Blair to retireWASHINGTON, Aug. 3, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or "the Company") announced that the Company's Board of Directors has appointed Julie Sawyer
WASHINGTON, July 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period
Linden Capital Partners ("Linden") and Audax Private Equity ("Audax"), two leading middle-market private equity firms, announced today an agreement to sell StatLab Medical Products ("StatLab" or
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
